To further study how SETD2 deficiency confers the upregulation of stem cells in imatinib‐resistant CML cell lines, we performed RNA sequencing on the TF1‐BA and TF1‐BAR cells. This evidence concerns the gene SETD2 and chronic myelogenous leukemia, BCR-ABL1 positive.